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Summary 
Blood monocytes from patients with active pulmonary tuberculosis and age-matched healthy 
purified protein derivative-reactive donors were infected with human immunodeficiency virus 
type 1 (HIV-1)jg.Ft in vitro to assess their susceptibility to productive infection by HIV-1. HIV-1 
p24 levels (enzyme-linked immunosorbent assay) in supernatants of infected cells from patients 
with tuberculosis,  albeit variable, were significantly higher at days 10-20 of culture; the maximum 
levels of p24 antigen were greater in supernatants of HIV-l-infected monocytes from patients 
than maximum levels for controls (P <0.05). The maximum increment in p24 levels for patients 
also exceeded that for controls (p <0.05). Entry of HIV-1 and/or initiation of reverse transcription, 
measured by polymerase chain reaction using HIV-1 R/U5 primer pairs, was variable and low 
in infected monocytes from both patients and controls, and did not correlate with HIV-1 p24 
levels. The frequency of infected cells as assessed by endpoint dilution viral cultures was similar 
for both groups. Therefore, blood monocytes from patients with active tuberculosis can develop 
a highly productive infection with HIV-1 that does not appear to be due to enhanced HIV entry 
or higher frequency of infected cells. The enhanced susceptibility may result directly from activation 
of monocytes by exposure to Mycobacterium tuberculosis and its products in situ. 
I 
nfection with HIV-1 appears to be responsible for the re- 
. cent rise in the prevalence of tuberculosis in the United 
States (1) and in developing countries (2-4). Among individ- 
uals infected with Mycobacterium tuberculosis, HIV-1 infection 
is the greatest known risk factor for development of active 
tuberculosis (5, 6). Furthermore, HIV-l-infected individuals 
have a high likelihood of developing progressive tuberculosis 
upon new infection with M.  tuberculosis (7). 
The impact of tuberculosis on HIV-1 disease is beginning 
to be recognized both in the United States (C. Whalen, per- 
sonal communication) and in other countries (8-10). Since 
tuberculosis tends to occur early in the course of HIV-1 dis- 
ease, the interaction of the two disease processes  may have 
a pronounced effect on viral burden and may facilitate  the 
progression of HIV-1 disease to advanced stages. Active tuber- 
culosis in the HIV-l-seronegative patient is associated  with 
several stigmas of activation of the immune system that may 
be conducive to enhancement of viral activity. Blood mono- 
cytes from patients with tuberculosis express markers of ac- 
tivation such as surface IL-2R (11) and production of TGF-3 
(12). Furthermore, upon in vitro stimulation with LPS and 
proteins of M. tuberculosis, monocytes from patients release 
increased amounts of TNF-o~ (13), IL-1 (14), and IL-6 (13). 
Studies of mononuclear cells from HIV-l-infected patients 
with tuberculosis also show enhanced purified protein deriva- 
tive (PPD)-stimulated TNF-c~ production at the time of di- 
agnosis of tuberculosis (10). IL-1, IL-6, and TNF-oe, in turn, 
are capable of enhancing HIV-1 production at several stages 
of viral replication (15).  Since circulating monocytes from 
tuberculous subjects appear to be primed in vivo with regard 
to a variety of functions, we postulated that these cells may 
display an enhanced in vitro susceptibility to infection with 
HIV-1. 
Materials and Methods 
Study Subjects.  Patients with newly diagnosed active pulmo- 
nary tuberculosis receiving care at Cleveland Veteran's Administra- 
tion Medical Center, University Hospitals of Cleveland, and Cleve- 
land MetroHealth Medical Center were recruited for study. The 
exclusion criteria were: >65 yr of age; antituberculous therapy for 
:>6 wk; concomitant debilitating illness, including malignancy, di- 
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for HIV-1. Diagnosis of tuberculosis was based on the demonstra- 
tion of acid-fast bacilli in sputum and was confirmed by a positive 
culture for M. tuberculosis. Each tuberculous patient was studied 
along with a healthy,  HIV-l-negative, and tuberculin-reactive age- 
matched subject. Two individuals  with pulmonary processes other 
than tuberculosis also were studied. One had a granulomatous dis- 
ease secondary to Histoplasma capsulatum. The second patient had 
an atypical lower lobe noncavitary pneumonia and was tuberculin 
reactive.  Both patients were subjected to the  same exclusionary 
criteria as patients with tuberculosis and were studied along with 
a healthy tuberculin-reactive subject.  None of the patients had fever 
at the time of study. All had hematocrits >30, and serum albumins 
>3.2  g/dl.  This protocol was approved by the Institutional  Re- 
view Boards of the above hospitals. 
Preparation of Cells.  PBMC  were  isolated  from  30  ml  of 
heparinized blood (20 U/ml) by centrifugation on Ficoll-Hypaque 
(Pharmacia Fine Chemicals, Piscataway, NJ) gradients (11). To ob- 
tain monocytes and nonadherent  (NA) cells, PBMC were resus- 
Pended at 5  x  106 cells/ml in RPMI  1640 (BioWhittaker,  Inc., 
Walkersville,  MD) with 10% (vol/vol) of heat-inactivated pooled 
human serum (PHS),  and incubated on plastic petri dishes  that 
were precoated with 1 ml of PHS. After 1 h plates were vortexed, 
NA cells were aspirated,  and plates were washed with prewarmed 
RPMI 1640 with 10% (vol/vol) FCS (HyClone Laboratories, Logan, 
UT). Adherent cells (ADH) were 90-95%  monocytes by peroxi- 
dase cytochemistry (11). NA cells were 70-80%  T  cells (OKT3 
reactive) and contained up to 5% peroxidase-reactive cells (mono- 
cytes). To further deplete NA cells from ADH,  the ADH were 
further incubated in RPMI 1640 with 10%  (vol/vol) PHS over- 
night and monolayers were washed before infection with HIV-1 
as described previously (16). This population was 99% peroxidase 
reactive and all monocytes by morphology (Wright cytostaining), 
and was >98%  viable by trypan blue staining. 
Infection of Cells with HIV-I.  The viral isolate used in this study 
was HIV-1jR.rt, which was recovered  from the frontal lobe brain 
of a patient with AIDS (16). This strain replicates in both activated 
lymphocytes and mononuclear phagocytes. Viral stock was prepared 
from 8-d culture supernatants of infected PHA-stimulated PBMC, 
quantitated for HIV-1 p24 antigen by ELISA, and the stocks were 
stored at  -70~  By limiting dilution assay on PHA-stimulated 
PBMC,  m30 pg of p24 was equivalent to one infectious unit of 
HIV-1. Before use, to deplete contaminating cell-associated proviral 
DNA, each aliquot of viral stock was filtered  through a 0.22-#m 
filter (Gelman Sciences Inc., Ann Arbor, MI) and was treated with 
1.8/~g/ml of RNAse-ffee DNAse (Worthington Biochemical Corp., 
Freehold, NJ) in the presence of 10 #M of MgC12. Cells were in- 
fected using the treated viral stock (400 ng p24/ml) together with 
polybrene (5/zg/ml) and were cultured for 2 h at 37~  Duplicate 
cultures received  heat-inactivated (HIA) virus (viral stock heated 
for I h at 56~  that had been DNAse treated and filtered as had 
the live virus. After incubation, virus-containing medium was aspi- 
rated and discarded,  and cells were washed twice with PBS. To 
remove cells, PBS containing 0.5 mM EDTA was added to plates 
for 10 min at room temperature. Then cells were scraped gently, 
sedimented at 1,500 rpm for 5 min, and resuspended in Iscove's 
medium (BioWhittaker, Inc.) containing 15% (vol/vol) PHS and 
5% (vol/vol) FCS (complete Iscove's). Cells were counted and plated 
at 5  x  10s/0.5 ml of complete Iscove's in wells of 24-well plates. 
Viability was assessed by trypan blue and was 99%. 
Detection of HIV-11o24 Antigen by ELISA.  Culture supernatants 
were collected every 4 d up to 20 d  after infection with HIV-1. 
The medium was changed 24 h before each collection. An enzyme- 
linked immunoassay kit for HIV-1 p24 antigen  (Coulter Immu- 
nology, Hialeah, FL) was used. This assay is sensitive to 7.5 pg/ml 
of p24 antigen. 
HIV-1 Detection by PCR.  After infection, monocytes were in- 
cubated at 5  x  103/0.5  ml of complete Iscove's for 24 h at 37~ 
The medium was removed and cells were washed once with PBS, 
and then lysed with 100/zl of lysis buffer (50 mM KC1,  10 mM 
Tris-HC1,  pH 8.3,  2.5  mM MgC12, 0.1  mg/ml gelatin  [Sigma 
Chemical Co., St. Louis, MO], 0.45% NP-40, 0.45% Tween 20, 
and 1 mg/ml proteinase K [Boehringer Mannheim Biochemicals, 
Indianapolis, IN]) (16). The cell lysates  were incubated at 60~ 
for  1 h  to  allow lysis of proteins by proteinase K  and  then  at 
95~  for 10 min to inactivate the proteinase K, and stored at -70~ 
until  use. 
The amplification reaction was carried out as described previ- 
ously (18). The 5' sense oligonucleotide primer for each pair was 
end labeled with y-[32p]ATP (ICN Laboratories,  lrvine, CA). Each 
reaction  contained  10  #1  of sample,  1.66  U  of taq  polymerase 
(Boehringer Mannheim Biochemicals),  50 ng of each HIV-1 primer, 
0.25 mM of each of the four dNTPs, 50 mM NaC1, 25 mM Tris- 
HC1,  pH  8.0,  5  mM  MgC12, and  0.1  mg/ml  BSA.  To  detect 
/~-globin  sequences,  25 ng of labeled  sense primer plus 25 ng of 
unlabeled antisense primer was used to reduce the intensity of the 
signal.  The total volume of the reaction mixture (25/~1) was over- 
layered with one drop of mineral oil and subjected to 25 cycles of 
denaturation at 94~  for 1 min and annealing and polymerization 
at 65~  for 2 rain. The primers used to detect HIV-1 sequences 
were M667/AA55, which amplifies a conserved region in the HIV-1 
LTR (R/US) 140 ofbp (18). The nucleotide sequences are: M667, 
5'GCTAACTAGGGAACCCA CTG-Y; AA55, 5'CTGCTAGAG- 
ATTTTCCACACTGAC-3'. Amplification of B-globin sequences 
was performed to normalize the amount of DNA content between 
samples. A primer pair that amplifies a 110-bp product in the first 
exon of the human fl-globin gene was used for this purpose (18). 
The sequences are 5'ACACAACTGTGTTCACTAGC-3' sense and 
5'CAACTTCATCCACGTTCACC-3'  antisense.  The  amplified 
products were separated electrophoretically  on a nondenaturing poly- 
acrylamide gel. The gel was dried and exposed to radiographic Kodak 
XAR-5  film for various periods of time at room temperature. 
To determine  the  number of copies of HIV-1 present  in  the 
amplified product of each reaction, known copy numbers of HIV-1 
DNA were prepared from cloned  HIV-1jR.csr DNA  (pNBjR.csF) 
linearized with EcolkI, which does not cleave viral sequences. HIV-1 
standards  of 3-3,000  copies  were  amplified  concurrently  with 
samples in each experiment.  HIV-l-negative PBMC DNA lysed 
with the same lysis buffer as test samples was used to prepare DNA 
standards (30-1,000 ng), and these standards  also were amplified 
concurrently with samples. 
Endpoint Dilution Viral Culture.  The titers of infectious HIVq 
of in vitro infected monocytes were determined using the endpoint 
dilution assay as described by Ho et al. (19). PBMC from a seronega- 
tive donor were stimulated with PHA (1 #g/ml) for 2 or 3 d and 
washed.  The PHA-stimulated PBMC then were suspended at 2 
x  106 cells/ml in growth medium that consisted of RPMI 1640, 
20%  FCS,  10%  IL-2 (Cellular  Products,  Buffalo,  NY),  2  /~M 
t-glutamine,  5 #g/ml gentamicin, and 50 U/ml penicillin.  1 ml 
of PBMC was placed in each well of a 24-well tissue culture plate. 
The monocytes were suspended in growth medium in fivefold di- 
lutions from 125  x  103 to 0.2  x  103 ceUs/ml.  1 ml of each dilu- 
tion of the adherent cells was added to the PHA-stimulated PBMC. 
One-half of the medium was changed twice per week with fresh 
growth medium without disturbing the cells at the bottom of the 
wells. Supernatants were collected every I wk for 4 wk and assayed 
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tive when the p24 antigen was 100 pg/ml or higher. The lowest 
dilution with a positive culture was considered the endpoint and 
the results were expressed  as tissue  culture infective  dose (TCID)/125 
x  103 cells. 
Statistical Analysis.  All HIV-1 p24 values were logarithmically 
transformed, and paired t tests were performed between each pa- 
tient control group. 
Results 
HIV-1  Infection of Monocytes from  Patients witk  Tubercu- 
losis.  Monocytes from five patients with tuberculosis and 
from five age-matched healthy individuals were infected with 
HIV-1]p,-FL as described in Materials and Methods. Superna- 
tants were collected for a 24-h period every 4 d after infec- 
tion and assayed for HIV-1 p24 by ELISA. Each panel in Fig. 
1 represents one patient-control pair studied. After day 8, 
patients had significantly higher values  of p24 in superna- 
tants at several time points: day 12, p <0.02; day 16, p <.05; 
and day 20, p <0.05. Levels of p24 in supernatants of mono- 
cytes from patients with tuberculosis were <2-60-fold higher 
than controls at day 12. The maximum p24 values in mono- 
cyte supernatants from patients were consistently greater than 
the maximum values for paired controls (p <0.05). The max- 
imum increments in p24 values during culture also were greater 
for patients than controls (p <0.05). As seen in Fig.  1, the 
degree of support of HIV production was variable among 
the patients. The maximal viral activity detected in superna- 
tants of monocytes from the patients over control subjects 
in Fig.  1, A  (50-fold) and C  (over 1000-fold),  was higher 
as contrasted with those in Fig.  1, B (3.4-fold), D (2-fold), 
and E  (1.6-fold).  However, even when the high producers 
were excluded from the analysis, the differences in HIV p24 
levels of supernatants of monocytes from patients with tuber- 
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Figure  2.  HIV-1 p24 levels (in pg/ml) in supernatants  of monocytes 
and NA cells. Monocytes and NA cells from each patient-control (.4 and 
B) pair were infected with HIV-1jR-FL  and culture supernatants  were as- 
sessed for p24 antigen produced over 24 h every 4 d by ELISA. Patient 
monocyte (O--O); patient NA cell (O-- -o); control monocyte (~-e); 
control NA (e- - -e). 
culosis and healthy individuals remained significantly higher 
on day 16 (p <0.05)  and day 20 (p <0.02). 
Since HIV-1j~-FL, although monocytotropic, also can in- 
fect activated primary T cells (18), it was necessary to assure 
that the high viral titers in cultures of infected monocytes 
from patients were not a reflection of infected activated lym- 
phocytes potentially contaminating preparations of mono- 
cytes. Therefore, in two patient-control pairs, NA cells, which 
are '~70-80% T lymphocytes and contain up to 5% mono- 
cytes, were infected in vitro with HIV-1JRFL in parallel with 
monocytes. Viral activity was assessed in NA culture super- 
natants at various periods thereafter by ELISA for p24 an- 
tigen. As shown in Fig.  2, viral activity in supernatants of 
NA cells was less than or equal, and never higher than super- 
natants of monocytes. These data indicate that the p24 an- 
tigen content of monocyte cell supernatants is not a result 
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Figure  1.  HIV-1 p24 levels (in 
pg/ml) in supernatants of mono- 
cytes from patients with tubercu- 
losis and healthy control subjects. 
Monocytes from each patient-con- 
trol pair were infected with HIV- 
1JR.-FL  and  culture  supernatants 
were assessed for p24 antigen pro- 
duced over 24 h every 4 d by ELISA. 
Each panel demonstrates results for 
one  patient-control pair.  Patient 
(O); control (O). 
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with tuberculosis and healthy control subjects by PCK. Monocytes (104 
cells) from a patient  (TB)--control  (C)  subject pair were infected with 
FIIV-1jg-FL, or HIA virus. At 24 h after infection,  cells were lysed and 
DNA amplification was performed using primer pairs specific  for fl-globin 
(.4), and for the HIV-1 R/U5 region using M667/AA55 primer pairs (B). 
Amplified products were resolved onto a gel and autoradiography was per- 
formed. Samples and known amounts ofPBMC DNA were amplified con- 
currently using the fl-globin primers to quantify cellular levels of DNA 
in the samples (.,4). Samples and known copy numbers  of HIV-1 DNA 
were amplified concurrently with the R/U5 primers  to quantify copies 
of Iqlv-1 (B). 
To assess if pulmonary processes other than tuberculosis 
increased the susceptibility of monocytes to productive in- 
fection with HIV-1, monocytes from a patient with pulmo- 
nary histoplasmosis,  a patient with atypical pneumonia, and 
a healthy control subject were infected with HIV-1jp.-FL;  cul- 
ture supematants were assessed  for HIV-1 p24 levels  over 24 h 
every 4 d, up to 20 d. The level of HIV-1 p24 culture super- 
natants of monocytes  from both patients remained lower than 
the healthy individual. Maximal levels were reached for each 
subject on day 12 of culture, and were 1,756 pg/ml for the 
patient with histoplasmosis, 3,038 pg/ml for the patient with 
atypical pneumonia, and D,000 pg/rrd for the control subject. 
HIV-1 DNA Synthesis in Monocytes  from Patients  with Tuber- 
culosis.  Enhanced HIV-1  production in  monocytes from 
tuberculous subjects could potentially be a result of early events 
in viral DNA synthesis after infection. To assess this possi- 
bility, we examined the load of HIV-1 DNA in the mono- 
cytes after infection. A semiquantitative PCR was performed 
on infected adherent cells using primer pairs (M667/AA55) 
that flank the start site of reverse transcription in the R/U5 
region of the LTR, and therefore detect all,  including in- 
complete, HIV-1 reverse transcripts. Monocytes from each 
patient-control pair (Fig.  1) were infected with HIV-1jFVL 
or with virus that was heat inactivated.  24 h after infection, 
cell lysates  were prepared as described in Materials and Methods 
for PCR analysis. The amount of total cellular DNA was 
quantified in each sample using human B-globin-specific oli- 
gonucleotide  primers. Concurrently, an equal volume of cell 
lysate was subjected to PCR using M667/AA55. A represen- 
tative experiment is shown in Fig. 3; both patient and con- 
trol had 300-1,000 copies of HIV-1/104 cells. The autora- 
diograms of the amplified HIV-1 R/U5 and globin products 
were analyzed by laser densitometry, and data for each pa- 
tient-control  pair  were  normalized to  the  densitometric 
readings of the globins. In four of five experiments HIV-1 
R/U5 product was higher in patients than controls (mean, 
2.1-fold) (Table 1). In one experiment HIV-1 R/U5 product 
was 1.9-fold higher in the control subject.  As seen in Table 
1, however, there was no corrdation between the HIV-1 R/U5 
data and HIV-1 p24 antigens in supernatants; the correla- 
tion coefficient for p24 levels and the HIV-1 R/U5 product 
was r  =  -0.05. These data indicated that viral entry and/or 
early events in reverse transcription in monocytes  were gener- 
ally higher in the monocytes from patients but were insufficient 
to explain the difference in the capacity to support a produc- 
tive viral infection. 
Frequency  oflnfecteclMonocytes.  To determine if the higher 
production of HIV-1 by monocytes  from patients with tuber- 
culosis could be attributed to an increased frequency of in- 
fected cells, endpoint dilution viral cultures were performed. 
Monocytes from patients and healthy controls (Fig.  1, A, 
C, and E) were infected with HIV-ljR-FL. Immediately after 
infection, fivefold serial dilutions of washed monocytes from 
patients and healthy individuals were cultured with PHA- 
stimulated PBMC in duplicate. To assure no carryover of free 
virus, the media from the last cell wash (postinfection) were 
cultured with PHA-stimulated PBMC. HIV-1 p24 antigen 
in culture supernatants was assessed weekly (up to 4 wk) and 
the frequency of HIV-l-positive cells calculated as TCID/125 
x  103 cells. In each of the three experiments performed, fre- 
quency of infected cells in the adherent cells ranged from 25 
to  125  TCID/125  x  103 and was  similar  in the patient- 
control pairs. HIV-1 p24 antigen was undetectable in the wash 
media. 
Discussion 
Blood monocytes from patients with active newly diag- 
nosed pulmonary tuberculosis were more susceptible  to a 
productive infection  with  HIV-1jp.-FL as  compared with 
monocytes from healthy PPD-reactive individuals.  Whereas 
differences in monocyte susceptibility to HIV-1jp.-~L  infection 
between some patients and concurrent control subjects were 
very high (50-1,000-fold),  in others these differences were 
more modest (mean, 2.3-fold).  The enhanced viral expres- 
sion by monocytes from patients was not due to a higher 
frequency of cells infected with HIV-1 during the primary 
infection or to early events after infection, including initia- 
tion of reverse transcription. 
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Determination of Reverse Transc@tion of HIV-1  in Infected 
Monocytes 
HIV-1  p24  HIV-1 
Exp.  on day 12  R/U5 
densitometric 
pg/ml  units* 
A  Patient  19,830  1,010 
59.3*  1.6s 
Control  334  600 
B  Patient  2,570  3,828 
6.2  4.1 
Control  413  922 
C  Patient  65,180  2,500 
14.0  1.4 
Control  4,647  1,699 
D  Patient  3,635  2,297 
2.7  1.4 
Control  1,351  1,639 
E  Patient  1,894  1,520 
1.4  0.52 
Control  1,355  2,912 
* Autoradiograms of the amplified HIV-1 R/U5 and globin products 
were analyzed by laser densitometry, and the area under curve  was ascribed 
arbitrary densitometric  units. In each patient-control experiment the globin 
readings were normalized to the globin reading from the control and 
IL/U5 densitometric readings corrected accordingly. 
* HIV-1 p24 in monocyte culture of patient/HIV-1 p24 in monocyte 
culture of control. 
$ HIV-1 R/U5 densitometric value in monocytes from patient/HIV-1 
R/U5 densitometric value in monocytes from control. 
The states of differentiation and activation of mononuclear 
phagocytes are determinants of infectability with HIV-1. Both 
alveolar macrophages, which are tissue macrophages differen- 
tiated from blood monocytes and activated in vivo presum- 
ably by chronic exposure to inhaled  antigens,  and in vitro 
cultured monocytes from healthy subjects support a produc- 
tive  infection  with  HIV-ljp.-FL,  whereas  freshly  isolated 
monocytes develop a minimally productive infection (16). In 
the current study, undifferentiated primary blood monocytes 
from healthy subjects again supported a low-level infection 
with HIV-1. Blood monocytes from tuberculous subjects ap- 
pear to be activated in vivo because a high percentage express 
IL-2R (11), produce TGF-~ (12),  and display high levels of 
intracellular  enzymatic activity (20). Furthermore, monocytes 
from patients with active tuberculosis are primed to increased 
production of cytokines upon in vitro stimulation (13,  14). 
Therefore, the increased susceptibility of monocytes from pa- 
tients with active pulmonary tuberculosis to productive in- 
fection with HIV-1jp.-FL in vitro may be a consequence of 
their activated state and may be mediated by cytokines. On 
the other hand, blood monocytes from a patient with newly 
diagnosed active pulmonary histoplasmosis and from a pa- 
tient with atypical pneumonia did not support viral expres- 
sion in vitro, suggesting a specificity to the observation during 
tuberculosis. The nature and abundance of mycobacterial pro- 
tein and lipid antigens to which mononuclear cells are ex- 
posed in situ may underlie the observed differences in HIV-1 
susceptibility of mononuclear phagocytes during tuberculosis 
as compared with other pulmonary processes. The variability 
in support of HIV production by monocytes from patients 
with active tuberculosis, however, may relate to differences 
in their  state of activation before HIV infection,  and may 
parallel  the variations in other markers  of activation,  such 
as IL-2R expression (11). In the infected cell many of the 
stages of HIV life cycle, such as completion of reverse tran- 
scription, integration within the host genome, and viral tran- 
scription, are dependent on the degree of cellular activation. 
Therefore, it is possible that in some patients, one or several 
of these stages are  affected. Whether  monocytes from pa- 
tients with tuberculosis also are more permissive targets to 
HIV strains other than  macrophage-tropic  strains,  such as 
HIV-1je.-FL, has not been studied. 
The increased viral expression in monocyte cultures from 
patients with tuberculosis was not due to contamination by 
T  lymphocytes. Morphologically, T  cells were not detected 
in monocyte populations prepared by overnight  adherence 
before infection. Furthermore,  T  lymphocytes require acti- 
vation by antigenic or mitogenic stimuli in vitro for a produc- 
tive infection by HIV-1 to ensue (18). Since our cultures were 
not stimulated in vitro, it is therefore particularly unlikely 
that our results can be attributed to infection of T lympho- 
cytes with  HIV-1.  Also,  the differences in p24 activity of 
NA cell cultures from patients and healthy controls in the 
present  study did not reflect differences in p24 activity of 
monocyte supernatants  from patients  and control subjects. 
The basis for the increased productive infection of mono- 
cytes from patients with active pulmonary tuberculosis with 
HIV-1  was examined.  There was no difference in  the fre- 
quency of infected monocytes from patients and healthy con- 
trols. Differences observed in the number of copies of HIV-1 
in infected monocytes from patients and controls using R/U5 
primer pairs that detect all initiated,  including incomplete, 
intermediate  and complete reverse transcripts  were variable 
and did not correlate with HIV-1 p24 levels in supernatants. 
Amplified products detected by this primer pair correlate with 
entry of virus in T  lymphocytes (18).  Thus,  the increased 
productive infection by monocytes from patients with tuber- 
culosis could not be attributed entirely to early events after 
infection, including HIV-1 entry or initiation of reverse tran- 
scription. We are presently investigating if the basis for en- 
hanced production of HIV-1 in monocytes from patients with 
tuberculosis is related to the increased production of or re- 
sponse to proinflammatory  cytokines in  these cells. 
Our in vitro findings of enhanced susceptibility of mono- 
cytes from patients with tuberculosis to productive infection 
1515  Toossi  et al.  Brief  Definitive Report with HIV-1 may indicate that, in the individual with dual 
infection (i.e., HIV-l-seropositive patient who develops tuber- 
culosis), a vast augmentation of viral load could occur both 
in the blood cells and within tissues.  We further speculate 
that the consequences to the dually infected host may be ac- 
celeration to AIDS and ultimately death. Future studies may 
correlate the association of excess production of proinflamma- 
tory cytokines with enhanced viral production in monocytes 
from patients with tuberculosis that are infected with HIV 
in vitro or in vivo. Trials of agents that block TNF-ot (21, 
22), in particular those that block TNF-oe more selectively, 
such as thalidomide (22),  may prove particularly useful in 
dually infected patients. 
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